Myosin light chain kinase inhibition potentiates the anti-tumor effects of avapritinib in PDGFRA D842V-mutant gastrointestinal stromal tumor.

Ferdinand Rossi,Mengyuan Liu,Andrew Tieniber,Mark S Etherington,Andrew Hanna,Gerardo A Vitiello,Nesteene J Param,Kevin Do,Laura Wang,Cristina R Antonescu,Shan Zeng,Jennifer Q Zhang,Ronald P DeMatteo

Clinical cancer research : an official journal of the American Association for Cancer Research（2023）

引用 0|浏览2

暂无评分

摘要

MYLK upregulation is a novel mechanism of tumor persistence after tyrosine kinase inhibition. Concomitant MYLK inhibition may enable the use of a lower dose of avapritinib, which is associated with dose-dependent cognitive side effects.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要